Brassard P, Frisch F, Lavoie F, Cyr D, Bourbonnais A, Cunnane S C, Patterson B W, Drouin R, Baillargeon J-P, Carpentier A C
Department of Medicine, Division of Endocrinology, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4.
J Clin Endocrinol Metab. 2008 Mar;93(3):837-44. doi: 10.1210/jc.2007-1670. Epub 2008 Jan 8.
Abnormal plasma nonesterified fatty acid (NEFA) metabolism may play a role in the development of type 2 diabetes.
Our objectives were to demonstrate whether there is a defect in insulin-mediated suppression of plasma NEFA appearance (RaNEFA) and oxidation (OxNEFA) during enhanced intravascular triacylglycerol lipolysis early in the natural history of type 2 diabetes, and if so, to determine whether other mechanisms than reduced insulin-mediated suppression of intracellular lipolysis are involved.
These are cross-sectional studies.
The studies were performed at an academic clinical research center.
Nine healthy subjects with both parents with type 2 diabetes (FH+) and nine healthy subjects with no first-degree relatives with type 2 diabetes (FH-) with similar anthropometric features were included in the studies.
Pancreatic clamps and iv infusion of stable isotopic tracers ([1,1,2,3,3-(2)H5]-glycerol and [U-(13)C]-palmitate or [1,2-(13)C]-acetate) were performed while intravascular triacylglycerol lipolysis was simultaneously clamped by iv infusion of heparin plus Intralipid at low (fasting) and high insulin levels. Oral nicotinic acid (NA) was used to inhibit intracellular lipolysis.
RaNEFA and OxNEFA were determined.
During heparin plus Intralipid infusion at high plasma insulin levels, and despite similar intravascular lipolytic rates, FH+ had higher RaNEFA and OxNEFA than FH- (RaNEFA: 17.4+/-6.3 vs. 9.2+/-4.2; OxNEFA: 4.5+/-1.8 vs. 2.3+/-1.5 micromol/kg lean body mass/min), independent of NA intake, gender, age, and body composition. In the presence of NA, insulin-mediated suppression of RaNEFA was still observed in FH-, but not in FH+.
Increased RaNEFA and OxNEFA during intravascular lipolysis at high insulin levels occur early in the natural history of type 2 diabetes.
血浆非酯化脂肪酸(NEFA)代谢异常可能在2型糖尿病的发生发展中起作用。
我们的目的是证明在2型糖尿病自然病程早期,强化血管内三酰甘油脂解过程中,胰岛素介导的抑制血浆NEFA生成(RaNEFA)和氧化(OxNEFA)是否存在缺陷,如果存在缺陷,确定是否涉及除胰岛素介导的抑制细胞内脂解以外的其他机制。
这些是横断面研究。
研究在一个学术临床研究中心进行。
9名父母均患有2型糖尿病的健康受试者(FH+)和9名无2型糖尿病一级亲属的健康受试者(FH-),他们具有相似的人体测量特征,被纳入研究。
进行胰腺钳夹和静脉输注稳定同位素示踪剂([1,1,2,3,3-(2)H5]-甘油和[U-(13)C]-棕榈酸或[1,2-(13)C]-乙酸),同时通过静脉输注肝素加中链脂肪酸甘油三酯在低(空腹)和高胰岛素水平下钳制血管内三酰甘油脂解。口服烟酸(NA)用于抑制细胞内脂解。
测定RaNEFA和OxNEFA。
在高血浆胰岛素水平下输注肝素加中链脂肪酸甘油三酯期间,尽管血管内脂解速率相似,但FH+的RaNEFA和OxNEFA高于FH-(RaNEFA:17.4±6.3对9.2±4.2;OxNEFA:4.5±1.8对2.3±1.5微摩尔/千克去脂体重/分钟),与NA摄入量、性别、年龄和身体组成无关。在存在NA的情况下,FH-中仍观察到胰岛素介导的对RaNEFA的抑制,但FH+中未观察到。
在2型糖尿病自然病程早期,高胰岛素水平下血管内脂解期间RaNEFA和OxNEFA增加。